These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 10401522

  • 1. Endogenous salivary inhibitors of human immunodeficiency virus.
    Shugars DC, Alexander AL, Fu K, Freel SA.
    Arch Oral Biol; 1999 Jun; 44(6):445-53. PubMed ID: 10401522
    [Abstract] [Full Text] [Related]

  • 2. Inhibitory function of secretory leukocyte proteinase inhibitor (SLPI) in human saliva is HIV-1 specific and varies with virus tropism.
    Skott P, Lucht E, Ehnlund M, Björling E.
    Oral Dis; 2002 May; 8(3):160-7. PubMed ID: 12108760
    [Abstract] [Full Text] [Related]

  • 3. Anatomic dissociation between HIV-1 and its endogenous inhibitor in mucosal tissues.
    Wahl SM, Worley P, Jin W, McNeely TB, Eisenberg S, Fasching C, Orenstein JM, Janoff EN.
    Am J Pathol; 1997 Apr; 150(4):1275-84. PubMed ID: 9094984
    [Abstract] [Full Text] [Related]

  • 4. Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-I.
    Wahl SM, McNeely TB, Janoff EN, Shugars D, Worley P, Tucker C, Orenstein JM.
    Oral Dis; 1997 May; 3 Suppl 1():S64-9. PubMed ID: 9456660
    [Abstract] [Full Text] [Related]

  • 5. Endogenous mucosal antiviral factors of the oral cavity.
    Shugars DC.
    J Infect Dis; 1999 May; 179 Suppl 3():S431-5. PubMed ID: 10099113
    [Abstract] [Full Text] [Related]

  • 6. Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type I.
    Shugars DC, Sauls DL, Weinberg JB.
    Oral Dis; 1997 May; 3 Suppl 1():S70-2. PubMed ID: 9456661
    [Abstract] [Full Text] [Related]

  • 7. The role of the oral environment in HIV-1 transmission.
    Shugars DC, Wahl SM.
    J Am Dent Assoc; 1998 Jul; 129(7):851-8. PubMed ID: 9685760
    [Abstract] [Full Text] [Related]

  • 8. Salivary secretory leukocyte protease inhibitor increases in HIV infection.
    Lin AL, Johnson DA, Stephan KT, Yeh CK.
    J Oral Pathol Med; 2004 Aug; 33(7):410-6. PubMed ID: 15250833
    [Abstract] [Full Text] [Related]

  • 9. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro.
    McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM.
    J Clin Invest; 1995 Jul; 96(1):456-64. PubMed ID: 7615818
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription.
    McNeely TB, Shugars DC, Rosendahl M, Tucker C, Eisenberg SP, Wahl SM.
    Blood; 1997 Aug 01; 90(3):1141-9. PubMed ID: 9242546
    [Abstract] [Full Text] [Related]

  • 11. Salivary concentration of secretory leukocyte protease inhibitor, an antimicrobial protein, is decreased with advanced age.
    Shugars DC, Watkins CA, Cowen HJ.
    Gerontology; 2001 Aug 01; 47(5):246-53. PubMed ID: 11490143
    [Abstract] [Full Text] [Related]

  • 12. Enhanced secretory leukocyte protease inhibitor in human immunodeficiency virus type 1-infected patients.
    Baqui AA, Meiller TF, Falkler WA.
    Clin Diagn Lab Immunol; 1999 Nov 01; 6(6):808-11. PubMed ID: 10548568
    [Abstract] [Full Text] [Related]

  • 13. Oral transmission of HIV, reality or fiction? An update.
    Campo J, Perea MA, del Romero J, Cano J, Hernando V, Bascones A.
    Oral Dis; 2006 May 01; 12(3):219-28. PubMed ID: 16700731
    [Abstract] [Full Text] [Related]

  • 14. Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk.
    Farquhar C, VanCott TC, Mbori-Ngacha DA, Horani L, Bosire RK, Kreiss JK, Richardson BA, John-Stewart GC.
    J Infect Dis; 2002 Oct 15; 186(8):1173-6. PubMed ID: 12355371
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Inhibitory effect of human saliva on HIV-1 infectivity].
    Etsuko K, Wei S.
    Nihon Rinsho Meneki Gakkai Kaishi; 2001 Aug 15; 24(4):152-9. PubMed ID: 16578966
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Secretory leukocyte protease inhibitor (SLPI): oxidation of SLPI does not explain its variable anti-HIV activity.
    Konopka K, Shine N, Pretzer E, Düzgüneş N.
    J Dent Res; 1999 Dec 15; 78(12):1773-6. PubMed ID: 10598905
    [Abstract] [Full Text] [Related]

  • 20. Anti-infectivity activity of human salivary secretions toward human immunodeficiency virus.
    Robinovitch MR, Iversen JM, Resnick L.
    Crit Rev Oral Biol Med; 1993 Dec 15; 4(3-4):455-9. PubMed ID: 8397002
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.